Iparomlimab and Tuvonralimab Clinical Trials in Nanjing, Jiangsu

Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.